| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Viaminate targets retinoic acid receptors (RARs), influencing cell differentiation, immune response, and fibrotic processes. As a retinoic acid derivative, it binds to retinoic acid receptors and modulates gene expression. The compound's effects on keratinization disorders and acne are mediated through regulation of epithelial cell differentiation and sebum production. Its hepatoprotective and anti-inflammatory properties suggest additional activities on liver cells and inflammatory pathways.
|
|---|---|
| ln Vitro |
Tretinoin and ethyl p-aminobenzoate combine to generate the amide chemical known as viaminate, in which the end group of Tretinoin is converted into an ester chain and an amide[1].
In vitro, Viaminate acts as a retinoic acid derivative that influences cell differentiation and immune response. As a vitamin A analog, it modulates gene expression through retinoic acid receptors (RARs). The compound's effects on keratinization and acne are mediated through regulation of epithelial cell differentiation. Viaminate also exhibits hepatoprotective and anti-inflammatory properties. However, detailed in vitro activity data including IC₅₀ values have not been extensively published. |
| ln Vivo |
In vivo, Viaminate is used for the treatment of severe acne and other keratinization disorders. It can be taken orally or applied topically in prepared gels and creams. As a retinoic acid derivative, it modulates cell differentiation and immune response, reducing the severity of acne and other keratinization disorders. The compound also exhibits hepatoprotective and anti-inflammatory properties. Viaminate is a pharmaceutical used in clinical practice.
|
| Enzyme Assay |
In vitro assays for Viaminate are not extensively documented in the available literature. As a retinoic acid derivative, potential assays could include evaluation of retinoic acid receptor (RAR) binding or activation using reporter gene assays. The compound's effects on cell differentiation can be assessed in keratinocyte or other epithelial cell cultures. Anti-inflammatory activity can be evaluated by measuring cytokine production in immune cells. The compound's purity is assessed by HPLC (≥98%).
|
| Cell Assay |
In vitro cellular assays for Viaminate could include evaluation of its effects on keratinocyte differentiation, sebocyte function, or immune cell modulation. Cells are treated with the compound and differentiation markers, cytokine production, or signaling pathway activation is measured. The compound's hepatoprotective effects can be assessed in liver cell models. Viaminate is typically handled as a solid and stored at 2-8°C.
|
| Animal Protocol |
In vivo animal experiments for Viaminate would have been conducted during its development as a pharmaceutical for acne and keratinization disorders. However, specific study protocols and results are not detailed in the available literature. The compound is used clinically for the treatment of severe acne and other keratinization disorders.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Viaminate have been characterized as part of its pharmaceutical development. The compound has a molecular weight of 447.61 g/mol and a molecular formula of C₂₉H₃₇NO₃. As a lipophilic retinoic acid derivative, it is expected to have good oral bioavailability and tissue distribution. Viaminate can be administered orally or topically. Storage: 2-8°C. Purity ≥98%.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Viaminate is consistent with other retinoids. As a retinoic acid derivative used for the treatment of severe acne and keratinization disorders, it may have teratogenic potential and other adverse effects associated with retinoid therapy, including mucocutaneous dryness, lipid abnormalities, and hepatotoxicity. Viaminate should not be used during pregnancy. The compound has hepatoprotective properties at therapeutic doses. Comprehensive toxicological data are available from the pharmaceutical literature.
|
| References |
[1]. Zhang H, et al. Fatal Hepatotoxicity Due to Viaminate. Am J Med Sci. 2018 Jul;356(1):84-86.
|
| Additional Infomation |
Viaminate (CAS# 53839-71-7, molecular formula C₂₉H₃₇NO₃, molecular weight 447.61) is a synthetic retinoic acid derivative used for the treatment of severe acne and other keratinization disorders. It targets retinoic acid receptors (RARs) and has hepatoprotective and anti-inflammatory properties. Can be taken orally or applied topically. No specific clinical trial information beyond existing approvals has been identified. Purity ≥98%. Storage: 2-8°C.
|
| Molecular Formula |
C29H37NO3
|
|---|---|
| Molecular Weight |
447.60898
|
| Exact Mass |
447.277
|
| CAS # |
53839-71-7
|
| Related CAS # |
(Z)-Viaminate;251441-94-8
|
| PubChem CID |
6438483
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.071 g/cm3
|
| Boiling Point |
619.4ºCat 760 mmHg
|
| Melting Point |
177-182 °C
|
| Flash Point |
328.4ºC
|
| LogP |
7.406
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
33
|
| Complexity |
846
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)C1=CC=C(C=C1)NC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C2=C(C)CCCC2(C)C
|
| InChi Key |
VRSMJNVXOITYPE-FSDIUQKZSA-N
|
| InChi Code |
InChI=1S/C29H37NO3/c1-7-33-28(32)24-14-16-25(17-15-24)30-27(31)20-22(3)11-8-10-21(2)13-18-26-23(4)12-9-19-29(26,5)6/h8,10-11,13-18,20H,7,9,12,19H2,1-6H3,(H,30,31)/b11-8+,18-13+,21-10+,22-20+
|
| Chemical Name |
ethyl 4-[[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2341 mL | 11.1704 mL | 22.3409 mL | |
| 5 mM | 0.4468 mL | 2.2341 mL | 4.4682 mL | |
| 10 mM | 0.2234 mL | 1.1170 mL | 2.2341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
